Taxorest
Khavinson natural peptide complex derived from bronchial tissue — the Cytomax counterpart to synthetic Bronchogen. Used for COPD, chronic bronchitis, and respiratory mucosal support.
🔬 Mechanism of Action
Taxorest is a Khavinson Cytomax derived from bronchial tissue — the natural extract counterpart to synthetic Bronchogen (AEDL). It contains multiple bronchial-specific peptides from ciliated epithelial cells, goblet cells, and submucosal glands.
Taxorest modulates: (1) ciliary dynein and tubulin expression for maintained mucociliary escalator function, (2) MUC5B mucin (healthy component) while downregulating MUC5AC (pathological in COPD), (3) beta-defensin-2 and lysozyme production for innate airway immunity, and (4) prostaglandin E2 pathway for balanced bronchial smooth muscle tone.
Taxorest's multi-peptide breadth makes it suited for comprehensive bronchial support, while Bronchogen (single tetrapeptide) offers more targeted gene activation. Often used in alternating cycles.
Source: PMID: 15677927
📜Background & History
Taxorest is the bronchial Cytomax extract — natural counterpart to synthetic Bronchogen.
🎯 Research Use Cases
- ✓Respiratory health
- ✓COPD support
- ✓Bronchial function
💉 Dosing Protocol
| Typical Dose | 1-2 capsules/day |
| Frequency | 1-2× daily for 10-30 day cycles |
| Half-Life | ~30 minutes (estimated) |
⚠️Safety & Considerations
Standard oral Cytomax capsule protocol. Well tolerated.
⚡Interactions & Contraindications
Standard Cytomax capsule protocol.
🔗Synergies & Common Stacks
Taxorest (Cytomax) + Bronchogen (synthetic) = layered respiratory support.